May 18, 2016 10:57am


BLCM named Jim Daly to its Board of Directors.  Daly has over 30 years experience leading U.S. and global businesses in the biopharmaceutical industry.  He was executive vice president and chief commercial officer at InCyte Corporation (INCY)from 2012 to 2015 where he  was responsible for commercializing and driving product growth of Jakafi®— the first drug approved by the U.S. FDA for patients to treat patients with polycythemia vera, a chronic type of bone marrow disease.  Previously, Daly worked for Amgen, Inc. (AMGN) and held various leadership positions over a 10-year period, including senior vice president, North America Commercial Operations, Global Marketing and Commercial Development.  Daly currently serves in director positions for Acadia Pharmaceuticals (ACAD), Halozyme Therapeutics (HALO), and Chimerix, Inc (CMRX).